Headshot
Guest

David Esposito

David Esposito is the Chief Executive Officer of ONL Therapeutics, an early-stage biotechnology company developing therapies for retinal disease. A West Point graduate, combat veteran, and experienced healthcare executive, David has spent more than 30 years leading organizations through growth, acquisitions, turnarounds, restructurings, and difficult wind-downs. His career includes serving as CEO of Armune BioScience, which was acquired by Exact Sciences, and President of Phadia US/AB, which was acquired by Thermo Fisher Scientific.

Today, he brings those experiences to ONL Therapeutics, where the company's vision is to help patients "see the future."

Guest appearance on: